LYCOS RETRIEVER 
Relenza: Patients
built 642 days ago
Relenza is an anti viral medication prescribed for the treatment of uncomplicated influenza virus. Relenza is used to treat type A and B influenza, the two most responsible for flu epidemics. Patients needed to start treatment within two days of the onset of symptoms for the drug to be effective.
Source:
Sir Richard dismissed criticisms that Relenza had not been tested on sufficient numbers of people with complications. UK Health Secretary Frank Dobson ... endorsing NICE's decision, has ordered more trials of the impact of the drug on patients at high risk of flu complications, such as the elderly and those with asthma. Mr Dobson plans to re-consider his recent decision in the light of those results in time for winter 2000/01.
Source:
Relenza is an anti viral medication beneficial for people suffering from influenza. It is highly effective in patients who have had symptoms for less than 2 days. It is ... helpful in reducing the transmission of the flu virus. The medication can be used for other purposes than those listed.
Source:
As for Relenza, 115 cases of psychiatric events have been reported, again mostly among people under 21 and in Japan (81%). Seven patients became delirious and developed impulsive behaviour, expressing fear, attempting to flee or expressing a desire to "jump". However none of these events were fatal.
Source:
In the event that a Relenza patient experienced difficulty breathing or wheezing this can indicate larger problems. Some Relenza patients have reported experiencing decline in lung function and bronchospasm. Individuals with chronic respiratory disease are advised to avoid Relenza due to the increased risk of side effects.
Source:
WASHINGTON – Food and Drug Administration experts are recommending new label warnings about possible dangerous psychiatric side effects of influenza drugs Tamiflu and Relenza, according to FDA documents. The documents, posted Friday on the FDA Web site, were prepared for a meeting Tuesday of the FDA's Pediatric Advisory Committee. Studies revealed 596 cases in which patients who took Tamiflu experienced "neuropsychiatric events" such as delirium, delusions or hallucinations. The episodes sometimes led to impulsive behavior and self-injury. Tamiflu is made by Roche Holdings.
Source:
MORE ABOUT
Patients